Gajiwala, Ketan S.
Pfizer (United States)
4 papers on CoChatORCID 0000-0003-0338-2529
Most cited papers
- Verified
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science
Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases
Cited by 4,451
- Verified
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Cited by 2,033
- Verified
Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes
Zhao, Q., Ouyang, X., Wan, X., Gajiwala, K. S., Kath, J. C., Jones, L. H., Burlingame, A. L., & Taunton, J. (2017) · Journal of the American Chemical Society
Click Chemistry and ApplicationsAdvanced Proteomics Techniques and Applications
Cited by 388
- Verified
Discovery of N-((3 R,4 R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H-pyrazol-4-yl)amino)-9-methyl-9 H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry
Lung Cancer Treatments and MutationsComputational Drug Discovery Methods
Cited by 97
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free